The autism spectrum disorders treatment market size has grown strongly in recent years. It will grow from $2.72 billion in 2023 to $2.89 billion in 2024 at a compound annual growth rate (CAGR) of 6.5%. The growth in the historical period is attributed to heightened awareness and improved diagnostic practices, advancements in therapeutic approaches, supportive government initiatives, advocacy efforts by parents and caregivers, and increased involvement of the educational system.
The autism spectrum disorders treatment market size is expected to see strong growth in the next few years. It will grow to $3.73 billion in 2028 at a compound annual growth rate (CAGR) of 6.6%. The growth in the forecast period is expected due to the increasing prevalence of Autism Spectrum Disorder (ASD), broader insurance coverage, the integration of technology in therapies, and global collaborative research efforts. Major trends anticipated in the forecast period include the implementation of early intervention strategies, the integration of Artificial Intelligence (AI), training programs for parents and caregivers, pharmacological interventions, and school-based and educational interventions.
The burgeoning prevalence of autism spectrum disorders (ASD) is expected to be a significant driving force behind the expansion of the autism spectrum disorders market in the foreseeable future. ASD encompasses a range of conditions characterized by challenges in social interaction and communication skills. The increasing identification of children with ASDs plays a pivotal role in driving the development of diverse treatment options tailored for this demographic. For instance, as per data from the Centers for Disease Control and Prevention (CDC) in 2021, one in 38 children aged eight years was diagnosed with autism spectrum disorders in the USA, with boys exhibiting 3.8 times higher prevalence than girls. Moreover, the prevalence of ASDs among children under 8 years was noted at 2.8%. This escalating prevalence of ASDs is anticipated to fuel growth within the autism spectrum disorders treatment market.
Rising healthcare expenditure emerges as a significant contributor propelling the growth of the autism spectrum disorders treatment market. The increase in funding allocated for ASD research, coupled with the implementation of early intervention programs and the incorporation of ASD therapies within healthcare coverage, plays a pivotal role in market expansion. For instance, data released by the Centers for Medicare & Medicaid Services (CMS) in June 2023 highlighted that the national health expenditure in the United States surged by 2.7% to reach $4.3 trillion in 2021, amounting to $12,914 per person and accounting for 18.3% of the Gross Domestic Product (GDP). Consequently, the escalating healthcare expenditure serves as a driving force propelling growth within the autism spectrum disorders treatment market.
Technology innovation within the autism spectrum disorders market has become a prominent trend. Researchers are directing their efforts toward pioneering advancements in the behavioral analysis of autism patients, aiming to cultivate social and occupational skills among children with autism. An illustration of this trend is evident in BrainCo Inc's December 2021 introduction of an innovative autism intervention method. This method leverages brain-computer interface technology, undergoing clinical trials in collaboration with the China Autism Rehabilitation Center, Shanghai Children’s Hospital, and Beijing Children’s Hospital. Combining a non-invasive EEG headband with computer-based games and exercises, this approach enables therapists to discern real-time brain activity patterns, monitor progress through interactions, and analyze facial expressions via eye contact observations.
Key players in the autism spectrum disorders treatment market are actively incorporating artificial intelligence (AI) to expedite and enhance the diagnosis of autism spectrum disorders. An example of this strategy is witnessed in Cognoa's initiative in June 2021. This US-based artificial intelligence developer introduced an algorithm specifically designed to aid clinicians in swiftly and accurately diagnosing autism in young children. The software operates by collating information obtained from parent, physician, and home video questionnaires, enabling it to provide recommendations to pediatricians for diagnosing patients.
In December 2022, MBF Healthcare Partners II, L.P., a healthcare-focused middle-market private equity firm based in the United States, successfully acquired ABA Connect for an undisclosed sum. Through this acquisition, MBF Healthcare Partners II, L.P., aims to broaden ABA Connect's services, extending support to children and families across Texas and other states in the USA. ABA Connect, a US-based provider of applied behavior analysis, utilizes evidence-based principles to improve the quality of life for children and families affected by autism spectrum disorders.
Major companies operating in the autism spectrum disorders treatment market report are Pfizer Inc., Johnson & Johnson Services Inc., Roche Holding AG, Novartis AG, Bristol-Myers Squibb, Teva Pharmaceuticals Industries Ltd., Otsuka Pharmaceutical Co. Ltd., Zenotech Laboratories Limited, Jazz Pharmaceuticals PLC, Alembic Pharmaceuticals Limited, 4D Pharma PLC, Acadia Pharmaceuticals Inc., Impel Pharmaceuticals Inc., Enterin Inc., Cognoa, BrainStorm Cell Therapeutics Inc., Axial Therapeutics Inc., Neurim Pharmaceuticals Inc., Curemark LLC, Yamo Pharmaceuticals LLC, Zynerba Pharmaceuticals Inc., Pax Medica, Stalicla SA, Neurotech International Limited, Confluence Pharmaceuticals LLC, MapLight Therapeutics Inc., SciSparc Ltd., Q BioMed Inc., Mercy Care, IAMA Therapeutics.
North America was the largest region in the autism spectrum disorders treatment market in 2023. The regions covered in the autism spectrum disorders treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the autism spectrum disorders treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The primary therapeutic approaches in autism spectrum disorder treatment involve the use of pharmaceuticals such as antipsychotic drugs, SSRIs or antidepressants, stimulants, sleep medications, and other drug therapies. Antipsychotic drugs are specifically employed to alleviate symptoms associated with schizophrenia and other psychotic conditions. The comprehensive treatment of autism spectrum disorders incorporates behavioral strategies, early intervention, and medication targeting specific conditions such as autistic disorder, Asperger syndrome, pervasive developmental disorder, among others. These treatment products are distributed through hospital pharmacies, retail pharmacies, drug stores, and online pharmacies.
The autism spectrum disorders treatment market research report is one of a series of new reports that provides autism spectrum disorders treatment market statistics, including the autism spectrum disorders treatment industry's global market size, regional shares, competitors with an autism spectrum disorders treatment market share, detailed autism spectrum disorders treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the autism spectrum disorders treatment industry. This autism spectrum disorders treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The autism spectrum disorders treatment market involves revenues earned by entities by providing therapies, assistive technologies, behavioral interventions, and education programs for treating and managing autism spectrum disorders (ASD). The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The autism spectrum disorders treatment market size is expected to see strong growth in the next few years. It will grow to $3.73 billion in 2028 at a compound annual growth rate (CAGR) of 6.6%. The growth in the forecast period is expected due to the increasing prevalence of Autism Spectrum Disorder (ASD), broader insurance coverage, the integration of technology in therapies, and global collaborative research efforts. Major trends anticipated in the forecast period include the implementation of early intervention strategies, the integration of Artificial Intelligence (AI), training programs for parents and caregivers, pharmacological interventions, and school-based and educational interventions.
The burgeoning prevalence of autism spectrum disorders (ASD) is expected to be a significant driving force behind the expansion of the autism spectrum disorders market in the foreseeable future. ASD encompasses a range of conditions characterized by challenges in social interaction and communication skills. The increasing identification of children with ASDs plays a pivotal role in driving the development of diverse treatment options tailored for this demographic. For instance, as per data from the Centers for Disease Control and Prevention (CDC) in 2021, one in 38 children aged eight years was diagnosed with autism spectrum disorders in the USA, with boys exhibiting 3.8 times higher prevalence than girls. Moreover, the prevalence of ASDs among children under 8 years was noted at 2.8%. This escalating prevalence of ASDs is anticipated to fuel growth within the autism spectrum disorders treatment market.
Rising healthcare expenditure emerges as a significant contributor propelling the growth of the autism spectrum disorders treatment market. The increase in funding allocated for ASD research, coupled with the implementation of early intervention programs and the incorporation of ASD therapies within healthcare coverage, plays a pivotal role in market expansion. For instance, data released by the Centers for Medicare & Medicaid Services (CMS) in June 2023 highlighted that the national health expenditure in the United States surged by 2.7% to reach $4.3 trillion in 2021, amounting to $12,914 per person and accounting for 18.3% of the Gross Domestic Product (GDP). Consequently, the escalating healthcare expenditure serves as a driving force propelling growth within the autism spectrum disorders treatment market.
Technology innovation within the autism spectrum disorders market has become a prominent trend. Researchers are directing their efforts toward pioneering advancements in the behavioral analysis of autism patients, aiming to cultivate social and occupational skills among children with autism. An illustration of this trend is evident in BrainCo Inc's December 2021 introduction of an innovative autism intervention method. This method leverages brain-computer interface technology, undergoing clinical trials in collaboration with the China Autism Rehabilitation Center, Shanghai Children’s Hospital, and Beijing Children’s Hospital. Combining a non-invasive EEG headband with computer-based games and exercises, this approach enables therapists to discern real-time brain activity patterns, monitor progress through interactions, and analyze facial expressions via eye contact observations.
Key players in the autism spectrum disorders treatment market are actively incorporating artificial intelligence (AI) to expedite and enhance the diagnosis of autism spectrum disorders. An example of this strategy is witnessed in Cognoa's initiative in June 2021. This US-based artificial intelligence developer introduced an algorithm specifically designed to aid clinicians in swiftly and accurately diagnosing autism in young children. The software operates by collating information obtained from parent, physician, and home video questionnaires, enabling it to provide recommendations to pediatricians for diagnosing patients.
In December 2022, MBF Healthcare Partners II, L.P., a healthcare-focused middle-market private equity firm based in the United States, successfully acquired ABA Connect for an undisclosed sum. Through this acquisition, MBF Healthcare Partners II, L.P., aims to broaden ABA Connect's services, extending support to children and families across Texas and other states in the USA. ABA Connect, a US-based provider of applied behavior analysis, utilizes evidence-based principles to improve the quality of life for children and families affected by autism spectrum disorders.
Major companies operating in the autism spectrum disorders treatment market report are Pfizer Inc., Johnson & Johnson Services Inc., Roche Holding AG, Novartis AG, Bristol-Myers Squibb, Teva Pharmaceuticals Industries Ltd., Otsuka Pharmaceutical Co. Ltd., Zenotech Laboratories Limited, Jazz Pharmaceuticals PLC, Alembic Pharmaceuticals Limited, 4D Pharma PLC, Acadia Pharmaceuticals Inc., Impel Pharmaceuticals Inc., Enterin Inc., Cognoa, BrainStorm Cell Therapeutics Inc., Axial Therapeutics Inc., Neurim Pharmaceuticals Inc., Curemark LLC, Yamo Pharmaceuticals LLC, Zynerba Pharmaceuticals Inc., Pax Medica, Stalicla SA, Neurotech International Limited, Confluence Pharmaceuticals LLC, MapLight Therapeutics Inc., SciSparc Ltd., Q BioMed Inc., Mercy Care, IAMA Therapeutics.
North America was the largest region in the autism spectrum disorders treatment market in 2023. The regions covered in the autism spectrum disorders treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the autism spectrum disorders treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The primary therapeutic approaches in autism spectrum disorder treatment involve the use of pharmaceuticals such as antipsychotic drugs, SSRIs or antidepressants, stimulants, sleep medications, and other drug therapies. Antipsychotic drugs are specifically employed to alleviate symptoms associated with schizophrenia and other psychotic conditions. The comprehensive treatment of autism spectrum disorders incorporates behavioral strategies, early intervention, and medication targeting specific conditions such as autistic disorder, Asperger syndrome, pervasive developmental disorder, among others. These treatment products are distributed through hospital pharmacies, retail pharmacies, drug stores, and online pharmacies.
The autism spectrum disorders treatment market research report is one of a series of new reports that provides autism spectrum disorders treatment market statistics, including the autism spectrum disorders treatment industry's global market size, regional shares, competitors with an autism spectrum disorders treatment market share, detailed autism spectrum disorders treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the autism spectrum disorders treatment industry. This autism spectrum disorders treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The autism spectrum disorders treatment market involves revenues earned by entities by providing therapies, assistive technologies, behavioral interventions, and education programs for treating and managing autism spectrum disorders (ASD). The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Autism Spectrum Disorders Treatment Market Characteristics3. Autism Spectrum Disorders Treatment Market Trends and Strategies32. Global Autism Spectrum Disorders Treatment Market Competitive Benchmarking33. Global Autism Spectrum Disorders Treatment Market Competitive Dashboard34. Key Mergers and Acquisitions in the Autism Spectrum Disorders Treatment Market
4. Autism Spectrum Disorders Treatment Market - Macro Economic Scenario
5. Global Autism Spectrum Disorders Treatment Market Size and Growth
6. Autism Spectrum Disorders Treatment Market Segmentation
7. Autism Spectrum Disorders Treatment Market Regional and Country Analysis
8. Asia-Pacific Autism Spectrum Disorders Treatment Market
9. China Autism Spectrum Disorders Treatment Market
10. India Autism Spectrum Disorders Treatment Market
11. Japan Autism Spectrum Disorders Treatment Market
12. Australia Autism Spectrum Disorders Treatment Market
13. Indonesia Autism Spectrum Disorders Treatment Market
14. South Korea Autism Spectrum Disorders Treatment Market
15. Western Europe Autism Spectrum Disorders Treatment Market
16. UK Autism Spectrum Disorders Treatment Market
17. Germany Autism Spectrum Disorders Treatment Market
18. France Autism Spectrum Disorders Treatment Market
19. Italy Autism Spectrum Disorders Treatment Market
20. Spain Autism Spectrum Disorders Treatment Market
21. Eastern Europe Autism Spectrum Disorders Treatment Market
22. Russia Autism Spectrum Disorders Treatment Market
23. North America Autism Spectrum Disorders Treatment Market
24. USA Autism Spectrum Disorders Treatment Market
25. Canada Autism Spectrum Disorders Treatment Market
26. South America Autism Spectrum Disorders Treatment Market
27. Brazil Autism Spectrum Disorders Treatment Market
28. Middle East Autism Spectrum Disorders Treatment Market
29. Africa Autism Spectrum Disorders Treatment Market
30. Autism Spectrum Disorders Treatment Market Competitive Landscape and Company Profiles
31. Autism Spectrum Disorders Treatment Market Other Major and Innovative Companies
35. Autism Spectrum Disorders Treatment Market Future Outlook and Potential Analysis
36. Appendix
Executive Summary
Autism Spectrum Disorders Treatment Global Market Report 2024 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on autism spectrum disorders treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
- Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
- Assess the Russia-Ukraine war’s impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
- Measure the impact of high global inflation on market growth.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis.
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for autism spectrum disorders treatment? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? This report answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.
- The impact of higher inflation in many countries and the resulting spike in interest rates.
- The continued but declining impact of COVID-19 on supply chains and consumption patterns.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Report Scope
Markets Covered:1) By Drug Therapy: Antipsychotic Drugs; SSRIs or Antidepressants; Stimulants; Sleep Medications; Other Drug Therapies
2) By Treatment Approach: Behavioral Approaches; Early Intervention; Medication
3) By Application: Autistic Disorder; Asperger Syndrome; Pervasive Developmental Disorder; Other Applications
4) By Distribution Channel: Hospital Pharmacies; Drug Stores and Retail Pharmacies; Online Pharmacies
Key Companies Mentioned: Pfizer Inc.; Johnson & Johnson Services Inc.; Roche Holding AG; Novartis AG; Bristol-Myers Squibb
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes
Delivery Format: PDF, Word and Excel Data Dashboard
Companies Mentioned
- Pfizer Inc.
- Johnson & Johnson Services Inc.
- Roche Holding AG
- Novartis AG
- Bristol-Myers Squibb
- Teva Pharmaceuticals Industries Ltd.
- Otsuka Pharmaceutical Co. Ltd.
- Zenotech Laboratories Limited
- Jazz Pharmaceuticals plc
- Alembic Pharmaceuticals Limited
- 4D Pharma plc
- Acadia Pharmaceuticals Inc.
- Impel Pharmaceuticals Inc
- Enterin Inc.
- Cognoa
- BrainStorm Cell Therapeutics Inc.
- Axial Therapeutics Inc.
- Neurim Pharmaceuticals Inc.
- Curemark LLC
- Yamo Pharmaceuticals LLC
- Zynerba Pharmaceuticals Inc.
- Pax Medica
- Stalicla SA
- Neurotech International Limited
- Confluence Pharmaceuticals LLC
- MapLight Therapeutics Inc.
- SciSparc Ltd.
- Q BioMed Inc.
- Mercy Care
- IAMA Therapeutics
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 175 |
| Published | February 2024 |
| Forecast Period | 2024 - 2028 |
| Estimated Market Value ( USD | $ 2.89 Billion |
| Forecasted Market Value ( USD | $ 3.73 Billion |
| Compound Annual Growth Rate | 6.6% |
| Regions Covered | Global |
| No. of Companies Mentioned | 30 |
